Arguments in favor of HPV testing for cervical screening and post-treatment CIN2+ monitoring

Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment

“…The Netherlands is due to commence HPV primary screening in 2016,2 the American Society for Clinical Pathology recommend this approach for women >303 in the USA and several European countries including the UK have implementation projects underway.…”

Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands

“…The specificity of the HR-HPV-test is however lower than cytology 90.7% (90.4-91.1%) and 96.3% (96.1-96.5%), respectively [6]. The test provides information about whether or not a woman has an infection with a HR-HPV type, but it does not provide information on the degree of transformation of cervical cells [7]. If a woman has a PAP3A2 or worse, she will be referred to a gynecologist [8].…”